Medline Inc.

- The company currently has about $2.2 billion of cash on hand and ended the quarter with 3.1x leverage. - Their primary focus is to invest excess cash into the business for organic growth. - They are open to pursuing M&A if the right strategic opportunities arise. - If no suitable M&A opportunities occur, excess capital will be used over time to reduce leverage. - There is no explicit mention of plans for new fundraising through debt or equity at this time. - The emphasis is on balancing investment in growth with disciplined capital management rather than raising new funds.

- Continued investments in sales to drive top-line growth. - Investments in operations to maintain best-in-industry service levels. - IT investments focusing on cybersecurity, AI capabilities, and warehouse management. - Building out service technician capacity, particularly in Canadian market expansion. - Strategic focus on leveraging AI with the Empower digital supply chain control tower to improve client performance and operational efficiency. - Long-term investment priority on organic growth first, with selective M&A pursued when right opportunities arise. - No specific dollar amounts for capital expenditures provided, but the emphasis is on sustaining growth and scaling operations amid challenging environment and tariff considerations.

- Raised full-year 2026 organic sales growth guidance to 8.5%–9.5%, up from 8%–9%, reflecting strong Q1 performance. - Strong momentum driven by new customer signings ($2.4 billion in 2025) and solid same-store sales growth. - Supply Chain Solutions delivered over 15% top-line growth in Q1, fueled by same-store growth and new customer implementations. - Expect some moderation in same-store sales growth in H2 2026 due to market uncertainties (ACA, ODBA). - U.S. non-acute business growing faster than acute, with continued share gains and robust demand across post-acute, surgery centers, and physician offices. - Long-term pipeline remains robust; about 50% of top 100 US health systems remain untapped, offering significant growth opportunity. - Confident in ability to capitalize on competitive dynamics, especially as competitors divest or face challenges. - Investing in operations, IT, and automation to support scalable growth and customer service excellence.

- Raised full-year 2026 organic sales growth guidance to 8.5% - 9.5%, up from previous 8% - 9% range, driven by strong Q1 sales and steady healthcare utilization. - Maintaining full-year adjusted EBITDA guidance at $3.5 billion to $3.6 billion despite input cost pressures and investments. - Expecting some sequential moderation in same-store sales growth in H2 2026 due to market uncertainties but confident in overall growth. - Investing heavily in operations, sales, IT, and automation to support durable, long-term growth and improved service levels. - Anticipate favorable tariff impacts offset by increased costs from Middle East conflict influencing margins; mitigation strategies ongoing. - New customer implementations and conversions, including $2.4 billion customer signings, provide a strong revenue growth pipeline. - Optimistic about continued market opportunity, especially in non-acute and multi-channel service segments, supporting sustainable earnings increases.

- The company reported a strong start to the year with $2.4 billion in total new customer signings for 2025. - Implementation ramp of these signings is underway, with about 25% revenue realization expected in 2025, 65% in 2026, and the remainder in 2027. - New prime vendor signings are progressing well, on track to achieve a goal of $1 billion in new prime vendor signings for the year. - The pipeline for new customer wins is described as very robust, with significant opportunities in healthcare consolidation. - No specific dollar amount was provided for pending or current orders beyond the 2025 signings and new prime vendor pipeline.